• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PINet 1.0:一种基于通路网络的特定疾病治疗药物组合评估方法。

PINet 1.0: A pathway network-based evaluation of drug combinations for the management of specific diseases.

作者信息

Hong Yongkai, Chen Dantian, Jin Yaqing, Zu Mian, Zhang Yin

机构信息

Institute of Health Service and Transfusion Medicine, Academy of Military Medical Sciences, Beijing, China.

出版信息

Front Mol Biosci. 2022 Oct 18;9:971768. doi: 10.3389/fmolb.2022.971768. eCollection 2022.

DOI:10.3389/fmolb.2022.971768
PMID:36330216
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9623281/
Abstract

Drug combinations can increase the therapeutic effect by reducing the level of toxicity and the occurrence of drug resistance. Therefore, several drug combinations are often used in the management of complex diseases. However, due to the exponential growth in drug development, it would be impractical to evaluate all combinations through experiments. In view of this, we developed Pathway Interaction Network (PINet) biological model to estimate the optimal drug combinations for various diseases. The random walk with restart (RWR) algorithm was used to capture the "disease state" and "drug state," while PINet was used to evaluate the optimal drug combinations and the high-order drug combination. The model achieved a mean area under the curve of a receiver operating characteristic curve of 0.885. In addition, for some diseases, PINet predicted the optimal drug combination. For example, in the case of acute myeloid leukemia, PINet correctly predicted midostaurin and gemtuzumab as effective drug combinations, as demonstrated by the results of a Phase-I clinical trial. Moreover, PINet also correctly predicted the potential drug combinations for diseases that lacked a training dataset that could not be predicted using standard machine learning models.

摘要

药物组合可以通过降低毒性水平和耐药性的发生来提高治疗效果。因此,几种药物组合经常用于复杂疾病的治疗。然而,由于药物研发呈指数级增长,通过实验评估所有组合是不切实际的。鉴于此,我们开发了通路相互作用网络(PINet)生物学模型来估计针对各种疾病的最佳药物组合。使用带重启的随机游走(RWR)算法来捕捉“疾病状态”和“药物状态”,而PINet则用于评估最佳药物组合和高阶药物组合。该模型在受试者工作特征曲线下的平均面积为0.885。此外,对于某些疾病,PINet预测了最佳药物组合。例如,在急性髓系白血病的病例中,PINet正确地预测了米哚妥林和吉妥单抗为有效的药物组合,一项I期临床试验的结果证明了这一点。此外,PINet还正确地预测了那些缺乏训练数据集、无法使用标准机器学习模型进行预测的疾病的潜在药物组合。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b87e/9623281/52b5ed10a2df/fmolb-09-971768-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b87e/9623281/cdf8449fa9a0/fmolb-09-971768-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b87e/9623281/126a7d39a246/fmolb-09-971768-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b87e/9623281/52b5ed10a2df/fmolb-09-971768-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b87e/9623281/cdf8449fa9a0/fmolb-09-971768-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b87e/9623281/126a7d39a246/fmolb-09-971768-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b87e/9623281/52b5ed10a2df/fmolb-09-971768-g004.jpg

相似文献

1
PINet 1.0: A pathway network-based evaluation of drug combinations for the management of specific diseases.PINet 1.0:一种基于通路网络的特定疾病治疗药物组合评估方法。
Front Mol Biosci. 2022 Oct 18;9:971768. doi: 10.3389/fmolb.2022.971768. eCollection 2022.
2
A Random Walk with Restart Model Based on Common Neighbors for Predicting the Clinical Drug Combinations on Coronary Heart Disease.基于公共邻居的重启动随机游走模型预测冠心病临床药物组合。
J Healthc Eng. 2021 Dec 8;2021:4597391. doi: 10.1155/2021/4597391. eCollection 2021.
3
Protein interaction interface region prediction by geometric deep learning.基于几何深度学习的蛋白质相互作用界面区域预测
Bioinformatics. 2021 Sep 9;37(17):2580-2588. doi: 10.1093/bioinformatics/btab154.
4
Deep graph embedding for prioritizing synergistic anticancer drug combinations.用于优先排序协同抗癌药物组合的深度图嵌入
Comput Struct Biotechnol J. 2020 Feb 15;18:427-438. doi: 10.1016/j.csbj.2020.02.006. eCollection 2020.
5
PINet: Privileged Information Improve the Interpretablity and generalization of structural MRI in Alzheimer's Disease.PINet:特权信息提升阿尔茨海默病中结构磁共振成像的可解释性和泛化能力。
ACM BCB. 2023 Sep;2023. doi: 10.1145/3584371.3613000. Epub 2023 Oct 4.
6
GADTI: Graph Autoencoder Approach for DTI Prediction From Heterogeneous Network.GADTI:基于异构网络的DTI预测的图自动编码器方法
Front Genet. 2021 Apr 9;12:650821. doi: 10.3389/fgene.2021.650821. eCollection 2021.
7
Predicting effective drug combinations using gradient tree boosting based on features extracted from drug-protein heterogeneous network.基于药物-蛋白质异质网络中提取的特征,使用梯度提升树来预测有效的药物组合。
BMC Bioinformatics. 2019 Dec 9;20(1):645. doi: 10.1186/s12859-019-3288-1.
8
Identifying Cancer genes by combining two-rounds RWR based on multiple biological data.基于多种生物数据的两轮 RWR 相结合识别癌症基因。
BMC Bioinformatics. 2019 Nov 25;20(Suppl 18):518. doi: 10.1186/s12859-019-3123-8.
9
Deep learning-based multi-drug synergy prediction model for individually tailored anti-cancer therapies.基于深度学习的多药协同预测模型,用于个性化定制抗癌疗法。
Front Pharmacol. 2022 Dec 15;13:1032875. doi: 10.3389/fphar.2022.1032875. eCollection 2022.
10
The drug cocktail network.药物鸡尾酒网络
BMC Syst Biol. 2012;6 Suppl 1(Suppl 1):S5. doi: 10.1186/1752-0509-6-S1-S5. Epub 2012 Jul 16.

本文引用的文献

1
Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.吉妥珠单抗奥佐米星联合米哚妥林与标准“7+3”诱导疗法治疗初诊 AML:SAL-MODULE Ⅰ期研究结果。
Br J Haematol. 2024 Jun;204(6):2254-2258. doi: 10.1111/bjh.19436. Epub 2024 Apr 9.
2
Bipartite network models to design combination therapies in acute myeloid leukaemia.二部网络模型设计急性髓细胞白血病的联合治疗方案。
Nat Commun. 2022 Apr 19;13(1):2128. doi: 10.1038/s41467-022-29793-5.
3
Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence.
利用图神经网络和协调多种证据进行 COVID-19 的药物再利用。
Sci Rep. 2021 Nov 30;11(1):23179. doi: 10.1038/s41598-021-02353-5.
4
Comparative analysis of molecular fingerprints in prediction of drug combination effects.分子指纹在预测药物联合效应中的比较分析。
Brief Bioinform. 2021 Nov 5;22(6). doi: 10.1093/bib/bbab291.
5
2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee.2021年美国心脏病学会(ACC)关于持续性高甘油三酯血症患者降低动脉粥样硬化性心血管疾病(ASCVD)风险管理的专家共识决策路径:美国心脏病学会解决方案集监督委员会报告
J Am Coll Cardiol. 2021 Aug 31;78(9):960-993. doi: 10.1016/j.jacc.2021.06.011. Epub 2021 Jul 28.
6
AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease.美国胃肠病学会中重度管腔及肛周瘘管型克罗恩病医学管理临床实践指南
Gastroenterology. 2021 Jun;160(7):2496-2508. doi: 10.1053/j.gastro.2021.04.022.
7
Network-based modeling of herb combinations in traditional Chinese medicine.基于网络的中药方剂组合建模。
Brief Bioinform. 2021 Sep 2;22(5). doi: 10.1093/bib/bbab106.
8
Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria.药物重用以开发新一代针对多重耐药菌的联合疗法。
Theranostics. 2021 Mar 4;11(10):4910-4928. doi: 10.7150/thno.56205. eCollection 2021.
9
HVIDB: a comprehensive database for human-virus protein-protein interactions.HVIDB:一个用于人类-病毒蛋白质相互作用的综合数据库。
Brief Bioinform. 2021 Mar 22;22(2):832-844. doi: 10.1093/bib/bbaa425.
10
9. Pharmacologic Approaches to Glycemic Treatment: .9. 血糖治疗的药物学方法: 。
Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124. doi: 10.2337/dc21-S009.